Newsletter | November 14, 2026

11.14.26 -- Life Science Leader Newsletter - Best Of October

OCTOBER'S BEST FEATURED EDITORIAL

The Case For Reciprocal Due Diligence In Life Sciences Board Recruitment

By DeeDee DeMan

Candidates for seats on company boards should carefully scrutinize governance, culture, and leadership dynamics before saying yes, writes DeeDee DeMan.

OCTOBER'S BEST INDUSTRY INSIGHTS

FDA Psychedelic Drug Guidance: What Sponsors Need To Know

FDA's July 2026 final guidance on psychedelic drug clinical investigations sets expectations for sponsors developing psilocybin, LSD, and MDMA therapies. Learn what it means for your program.

The Best Regulatory Practices For Lifecycle Management

Discover how Quality by Design strategies can reduce regulatory burden, simplify post-approval changes, and improve lifecycle flexibility while maintaining product quality and supply continuity.

When Do AI Models Need To Be Validated For Regulated Industries?

Focus AI validation on decision impact rather than just algorithms. Aligning assurance with intended use and human oversight ensures safety while enabling faster, more compliant adoption.

Connect With Life Science Leader: